The Filings Report

Zimmer Biomet Holdings, Inc.

ZBHNYSECIK 1136869Healthcare / Medical Devicesfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$2.2B
+4.8% on Q2 FY2025
Net income
$198M
+29.8% on Q2 FY2025
Free cash flow
$394M
+20.0% on Q2 FY2025
Diluted EPS
$1.03
+33.8% on Q2 FY2025
Revenue, TTM
$8.5B
trailing four quarters
Net margin, TTM
9.5%
net income $807M
Free cash flow, TTM
$1.5B
$1.7B less $220M capex
Cash and equivalents
$410M
long-term debt $6.3B, Jun 30, 2026
Shares, 12-month change
−3.7%
191M shares, Jun 30, 2026
Buybacks, TTM
$751M
4.2% of market value
Dividends, TTM
$188M
1.1% of market value
Market value
$18.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Zimmer Biomet Holdings, Inc. reported revenue of $2.2B, +4.8% on Q2 FY2025, and net income of $198M (+29.8%). Operating margin was 15.0%. Free cash flow, operating cash flow less capital expenditures, was $394M ($448M less $54M). Diluted earnings per share were $1.03.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$1B$0$1B$2B$3BQ3'22, Revenue: $1.7BQ3'22, Net income: $194MQ3'22Q4'22, Revenue: $1.8BQ4'22, Net income: −$131MQ4'22Q1'23, Revenue: $1.8BQ1'23, Net income: $233MQ1'23Q2'23, Revenue: $1.9BQ2'23, Net income: $210MQ2'23Q3'23, Revenue: $1.8BQ3'23, Net income: $163MQ3'23Q4'23, Revenue: $1.9BQ4'23, Net income: $419MQ4'23Q1'24, Revenue: $1.9BQ1'24, Net income: $172MQ1'24Q2'24, Revenue: $1.9BQ2'24, Net income: $243MQ2'24Q3'24, Revenue: $1.8BQ3'24, Net income: $249MQ3'24Q4'24, Revenue: $2.0BQ4'24, Net income: $240MQ4'24Q1'25, Revenue: $1.9BQ1'25, Net income: $182MQ1'25Q2'25, Revenue: $2.1BQ2'25, Net income: $153MQ2'25Q3'25, Revenue: $2.0BQ3'25, Net income: $231MQ3'25Q4'25, Revenue: $2.2BQ4'25, Net income: $139MQ4'25Q1'26, Revenue: $2.1BQ1'26, Net income: $238MQ1'26Q2'26, Revenue: $2.2BQ2'26, Net income: $198MQ2'26−$1B$0$1B$2B$3BQ3'22, Revenue: $1.7BQ3'22, Net income: $194MQ4'22, Revenue: $1.8BQ4'22, Net income: −$131MQ4'22Q1'23, Revenue: $1.8BQ1'23, Net income: $233MQ2'23, Revenue: $1.9BQ2'23, Net income: $210MQ2'23Q3'23, Revenue: $1.8BQ3'23, Net income: $163MQ4'23, Revenue: $1.9BQ4'23, Net income: $419MQ4'23Q1'24, Revenue: $1.9BQ1'24, Net income: $172MQ2'24, Revenue: $1.9BQ2'24, Net income: $243MQ2'24Q3'24, Revenue: $1.8BQ3'24, Net income: $249MQ4'24, Revenue: $2.0BQ4'24, Net income: $240MQ4'24Q1'25, Revenue: $1.9BQ1'25, Net income: $182MQ2'25, Revenue: $2.1BQ2'25, Net income: $153MQ2'25Q3'25, Revenue: $2.0BQ3'25, Net income: $231MQ4'25, Revenue: $2.2BQ4'25, Net income: $139MQ4'25Q1'26, Revenue: $2.1BQ1'26, Net income: $238MQ2'26, Revenue: $2.2BQ2'26, Net income: $198MQ2'26

Net income losses drawn in red.

Free cash flow
$0$200M$400M$600MQ3'22Q4'22Q1'23, Free cash flow: $261MQ1'23Q2'23, Free cash flow: $251MQ2'23Q3'23, Free cash flow: $253MQ3'23Q4'23, Free cash flow: $526MQ4'23Q1'24, Free cash flow: $173MQ1'24Q2'24, Free cash flow: $317MQ2'24Q3'24, Free cash flow: $351MQ3'24Q4'24, Free cash flow: $455MQ4'24Q1'25, Free cash flow: $338MQ1'25Q2'25, Free cash flow: $328MQ2'25Q3'25, Free cash flow: $364MQ3'25Q4'25, Free cash flow: $443MQ4'25Q1'26, Free cash flow: $323MQ1'26Q2'26, Free cash flow: $394MQ2'26$0$200M$400M$600MQ4'22Q1'23, Free cash flow: $261MQ2'23, Free cash flow: $251MQ2'23Q3'23, Free cash flow: $253MQ4'23, Free cash flow: $526MQ4'23Q1'24, Free cash flow: $173MQ2'24, Free cash flow: $317MQ2'24Q3'24, Free cash flow: $351MQ4'24, Free cash flow: $455MQ4'24Q1'25, Free cash flow: $338MQ2'25, Free cash flow: $328MQ2'25Q3'25, Free cash flow: $364MQ4'25, Free cash flow: $443MQ4'25Q1'26, Free cash flow: $323MQ2'26, Free cash flow: $394MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$2B$4B$6B$8BQ3'22, Cash and equivalents: $545MQ3'22, Long-term debt: $5.1BQ3'22Q4'22, Cash and equivalents: $376MQ4'22, Long-term debt: $5.2BQ4'22Q1'23, Cash and equivalents: $330MQ1'23, Long-term debt: $5.2BQ1'23Q2'23, Cash and equivalents: $320MQ2'23, Long-term debt: $5.2BQ2'23Q3'23, Cash and equivalents: $292MQ3'23, Long-term debt: $5.1BQ3'23Q4'23, Cash and equivalents: $416MQ4'23, Long-term debt: $4.9BQ4'23Q1'24, Cash and equivalents: $393MQ1'24, Long-term debt: $4.8BQ1'24Q2'24, Cash and equivalents: $420MQ2'24, Long-term debt: $4.0BQ2'24Q3'24, Cash and equivalents: $569MQ3'24, Long-term debt: $4.7BQ3'24Q4'24, Cash and equivalents: $526MQ4'24, Long-term debt: $5.3BQ4'24Q1'25, Cash and equivalents: $1.4BQ1'25, Long-term debt: $6.6BQ1'25Q2'25, Cash and equivalents: $557MQ2'25, Long-term debt: $6.8BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $7.5BQ3'25Q4'25, Cash and equivalents: $592MQ4'25, Long-term debt: $6.9BQ4'25Q1'26, Cash and equivalents: $424MQ1'26, Long-term debt: $6.3BQ1'26Q2'26, Cash and equivalents: $410MQ2'26, Long-term debt: $6.3BQ2'26$0$2B$4B$6B$8BQ3'22, Cash and equivalents: $545MQ3'22, Long-term debt: $5.1BQ4'22, Cash and equivalents: $376MQ4'22, Long-term debt: $5.2BQ4'22Q1'23, Cash and equivalents: $330MQ1'23, Long-term debt: $5.2BQ2'23, Cash and equivalents: $320MQ2'23, Long-term debt: $5.2BQ2'23Q3'23, Cash and equivalents: $292MQ3'23, Long-term debt: $5.1BQ4'23, Cash and equivalents: $416MQ4'23, Long-term debt: $4.9BQ4'23Q1'24, Cash and equivalents: $393MQ1'24, Long-term debt: $4.8BQ2'24, Cash and equivalents: $420MQ2'24, Long-term debt: $4.0BQ2'24Q3'24, Cash and equivalents: $569MQ3'24, Long-term debt: $4.7BQ4'24, Cash and equivalents: $526MQ4'24, Long-term debt: $5.3BQ4'24Q1'25, Cash and equivalents: $1.4BQ1'25, Long-term debt: $6.6BQ2'25, Cash and equivalents: $557MQ2'25, Long-term debt: $6.8BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25, Long-term debt: $7.5BQ4'25, Cash and equivalents: $592MQ4'25, Long-term debt: $6.9BQ4'25Q1'26, Cash and equivalents: $424MQ1'26, Long-term debt: $6.3BQ2'26, Cash and equivalents: $410MQ2'26, Long-term debt: $6.3BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Zimmer Biomet Holdings, Inc. income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue2,1772,0872,2442,0012,0771,9092,0231,824+4.8%
Cost of revenue636576792559592550587539+7.3%
Gross profit—————————
Research and development—————————
Selling, general and administrative899850872811815759747710+10.4%
Operating income326373155351300292389280+8.7%
Other income (expense)2(3)15343(38)5−51.3%
Pretax income25530198279225229289230+13.6%
Income tax5663(40)48714749(19)−22.1%
Net income198238139231153182240249+29.8%
Diluted EPS ($)1.031.22—1.160.770.91—1.23+33.8%
Diluted shares (millions)193196—199198200—203—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Zimmer Biomet Holdings, Inc. balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents4104245921,2935571,385526569−26.4%
Short-term investments—————————
Total current assets5,0974,9635,1205,8355,0545,5904,6724,864+0.8%
Total assets22,79822,72223,09223,48822,86522,18421,36521,720−0.3%
Total current liabilities3,0142,8642,5842,4032,7002,2952,4513,571+11.6%
Long-term debt6,2786,2956,9327,5136,7536,5765,3424,738−7.0%
Total liabilities10,16510,04010,38610,72210,3319,7808,8899,337−1.6%
Stockholders’ equity12,62412,67312,69812,75712,52512,39512,46812,375+0.8%
Shares outstanding (millions)191193196198198198199199—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

Zimmer Biomet Holdings, Inc. cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 1, 2026Q4 FY2025ended Dec 31, 2025filed Feb 20, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Aug 7, 2025Q1 FY2025ended Mar 31, 2025filed May 5, 2025Q4 FY2024ended Dec 31, 2024filed Feb 25, 2025Q3 FY2024ended Sep 30, 2024filed Oct 30, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow448359517419378383506396+18.4%
Capital expenditures5436755550455245+8.2%
Free cash flow (CFO − capex)394323443364328338455351+20.0%
Depreciation and amortization271270284284272254264251−0.4%
Share repurchases2512502500723072596+3381.9%
Dividends paid4747484848484849−2.1%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 20, 2026.

Income statement

Zimmer Biomet Holdings, Inc. income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 23, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Feb 25, 2010FY2008ended Dec 31, 2008filed Aug 17, 2009FY2007ended Dec 31, 2007filed Aug 17, 2009
Revenue8,2327,6797,3946,9406,8276,1287,9827,9337,8037,668—————4,2204,0954,1213,898
Cost of revenue2,4942,1912,0842,0201,9601,8242,2532,2722,1332,382—————1,012991997876
Gross profit———————————3,4243,3373,3473,3303,2083,1053,1243,022
Research and development—————————————226238219———
Selling, general and administrative3,2572,9302,8392,7622,8432,7133,3443,3793,1052,9452,2841,7511,7491,8071,8341,7591,7291,7041,517
Operating income1,0981,2861,278696860831,138347998214671,0371,0691,0471,0249171,0191,0901,128
Other income (expense)26(31)(9)(128)1224(5)(16)(9)(66)(37)(47)———————
Pretax income8311,0371,067404499(105)906(271)4654001539391,0089909798609981,1221,132
Income tax1261314211254(96)(226)108(1,349)957220230237219263281272358
Net income7059041,024231402(139)1,132(379)1,814306147720780755761597717849773
Diluted EPS ($)3.554.434.881.101.91(0.67)5.47(1.86)8.901.510.774.204.544.294.032.973.323.723.26
Diluted shares (millions)199204210210210207207204204202190172172176189201216228238

Balance sheet

Zimmer Biomet Holdings, Inc. balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 23, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Feb 25, 2010FY2008ended Dec 31, 2008filed Aug 17, 2009FY2007ended Dec 31, 2007filed Aug 17, 2009
Cash and equivalents5925264163763788026185435246341,4591,0831,081884768669692213464
Short-term investments——————————16561372767245626566——
Total current assets5,1204,6724,6104,4274,8855,0834,7244,4274,5654,6645,8544,3134,1983,7093,2773,0102,7382,179—
Total assets23,09221,36521,49721,06623,45624,41824,63924,12726,01426,68427,1619,6589,5959,0128,5158,0007,7867,239—
Total current liabilities2,5842,4512,8572,3583,4682,5573,4422,4213,0702,3821,6181,0241,032866867703691771—
Long-term debt6,9325,3424,8685,1521,0007,6276,7218,4148,91810,66611,4971,4261,6721,7211,5761,1421,128460—
Total liabilities10,3868,8899,0099,03910,79012,21812,24612,85114,27917,01517,2713,1063,2813,1463,0012,2292,1471,585—
Stockholders’ equity12,69812,46812,48112,02012,66112,19412,38811,27111,7369,6699,8886,5506,2975,8615,5075,7715,6395,650—
Shares outstanding (millions)196199205209209208206204203201199170169169178192203——

Cash flow statement

Zimmer Biomet Holdings, Inc. cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 20, 2026FY2024ended Dec 31, 2024filed Feb 25, 2025FY2023ended Dec 31, 2023filed Feb 23, 2024FY2022ended Dec 31, 2022filed Feb 24, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 22, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 26, 2019FY2017ended Dec 31, 2017filed Feb 27, 2018FY2016ended Dec 31, 2016filed Mar 1, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Feb 23, 2015FY2013ended Dec 31, 2013filed Feb 28, 2014FY2012ended Dec 31, 2012filed Feb 27, 2013FY2011ended Dec 31, 2011filed Feb 27, 2012FY2010ended Dec 31, 2010filed Feb 25, 2011FY2009ended Dec 31, 2009filed Feb 25, 2010FY2008ended Dec 31, 2008filed Aug 17, 2009FY2007ended Dec 31, 2007filed Aug 17, 2009
Operating cash flow1,6971,4991,582—1,4991,2051,5861,7471,5821,632——9631,1521,1771,1941,1181,0381,084
Capital expenditures22520429118814411220716315618516814510011511479105250193
Free cash flow (CFO − capex)1,4731,2961,291—1,3561,0931,3791,5851,4261,448——8631,0371,0631,1141,012788892
Depreciation and amortization1,0949969529269388981,0061,0411,0631,039712376359363360340337275230
Share repurchases487868692126—————4161504017214861,050506924737576
Dividends paid19019620120120019919719519418815714613294—————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$824K
2 sales by 2 insiders; officers and directors $824K
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$2M
6 sales by 4 insiders; officers and directors $2M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Oct 1, 2026Campbell Gary CraigPresident, Americasoption exercise2,368$0.00—2,368Oct 5, 2026
Oct 1, 2026Campbell Gary CraigPresident, Americastax withholding932$88.42$82K1,436Oct 5, 2026
Oct 1, 2026Campbell Gary CraigPresident, Americasoption exercise1,218$0.00—2,654Oct 5, 2026
Oct 1, 2026Campbell Gary CraigPresident, Americastax withholding480$88.42$42K2,174Oct 5, 2026
Sep 11, 2026Thornal Kevin RGrp Pres-Global Businessopen-market sale5,691$92.95$529K0Sep 15, 2026
Sep 4, 2026Phipps Chad FSee remarks below.open-market sale3,000$98.35$295K65,231Sep 9, 2026
Aug 1, 2026Thornal Kevin RGrp Pres-Global Businessoption exercise9,957$0.00—9,957Aug 4, 2026
Aug 1, 2026Thornal Kevin RGrp Pres-Global Businesstax withholding4,266$92.68$395K5,691Aug 4, 2026
May 29, 2026Yi SangGroup President, Asia Pacificopen-market sale4,200$82.64$347K28,051Jun 2, 2026
May 29, 2026Yi SangGroup President, Asia Pacificopen-market sale800$82.66$66K27,251Jun 2, 2026
Apr 1, 2026Noor JehanzebSee remarks below.option exercise6,626$0.00—6,828Apr 3, 2026
Apr 1, 2026Noor JehanzebSee remarks below.tax withholding1,677$90.67$152K5,151Apr 3, 2026
Mar 12, 2026Winkler LoriSVP and CHROopen-market sale2,650$94.66$251K10,224Mar 16, 2026
Mar 6, 2026Upadhyay SuketuExec VP, CFOtax withholding4,547$92.54$421K66,955Mar 10, 2026
Mar 6, 2026Upadhyay SuketuExec VP, CFOoption exercise10,217$0.00—71,502Mar 10, 2026
Mar 6, 2026Upadhyay SuketuExec VP, CFOoption exercise4,559$0.00—71,514Mar 10, 2026
Mar 6, 2026Upadhyay SuketuExec VP, CFOtax withholding2,029$92.54$188K69,485Mar 10, 2026
Mar 6, 2026Van Zuilen WilfredGroup Pres, EMEAoption exercise2,161$0.00—31,553Mar 10, 2026
Mar 6, 2026Van Zuilen WilfredGroup Pres, EMEAtax withholding562$92.54$52K30,991Mar 10, 2026
Mar 6, 2026Van Zuilen WilfredGroup Pres, EMEAtax withholding1,260$92.54$117K29,392Mar 10, 2026
Mar 6, 2026Van Zuilen WilfredGroup Pres, EMEAoption exercise4,843$0.00—30,652Mar 10, 2026
Mar 6, 2026Winkler LoriSVP and CHROoption exercise1,699$0.00—13,503Mar 10, 2026
Mar 6, 2026Winkler LoriSVP and CHROtax withholding629$92.54$58K12,874Mar 10, 2026
Mar 6, 2026Winkler LoriSVP and CHROtax withholding1,549$92.54$143K11,804Mar 10, 2026
Mar 6, 2026Winkler LoriSVP and CHROoption exercise3,935$0.00—13,353Mar 10, 2026

Full insider history for Zimmer Biomet Holdings, Inc., or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
ZIMMER BIOMET HOLDINGS, INC., CIK 1136869 on EDGAR
Extract generated
November 1, 2026
Withheld
3 line-years whose four quarters do not sum to the filed year: net income FY2013, gross profit FY2014, revenue FY2020
Repaired
3 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: operating income FY2018, other income FY2019, income tax FY2023
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/ZBH.json